title: Longitudinal JCV serology in multiple sclerosis patients preceding natalizumab-associated progressive multifocal leukoencephalopathy.
abstract: The presence of anti-John Cunningham Virus (JCV) antibodies is a risk factor for the development of progressive multifocal leukoencephalopathy (PML) in MS patients treated with natalizumab. It has been suggested that an increase in serum anti-JCV antibody index precedes the development of PML. We here describe extensive longitudinal serum anti-JCV antibody indexes of four MS patients who developed PML. Anti-JCV antibodies were measured using the STRATIFY JCV™DxSelect™ test. All four patients had rather stable high anti-JCV antibody indexes in all samples obtained before developing PML. Possibly caused by reaching the saturation level of the assay, no increase in anti-JCV antibody indexes was seen just before the diagnosis of PML. This study confirms that high serum anti-JCV antibody indexes precede natalizumab-associated PML.
authors: Department of Neurology, MS Centre Amsterdam, VU Medical Centre, The Netherlands a.vennegoor@vumc.nl.
authors: Anke
authors: A
authors: Vennegoor
authors: Department of Neurology, MS Centre Amsterdam, VU Medical Centre, The Netherlands.
authors: Johannis A
authors: JA
authors: van Rossum
authors: Department of Neurology, MS Centre Amsterdam, VU Medical Centre, The Netherlands.
authors: Chris H
authors: CH
authors: Polman
authors: Department of Radiology, MS Centre Amsterdam, VU Medical Centre, The Netherlands.
authors: Mike P
authors: MP
authors: Wattjes
authors: Department of Neurology, MS Centre Amsterdam, VU Medical Centre, The Netherlands.
authors: Joep
authors: J
authors: Killestein
mesh_terms: D000328:Adult; D000914:Antibodies, Viral / Q000097:blood*; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects*; D007577:JC Virus / Q000276:immunology*; D007968:Leukoencephalopathy, Progressive Multifocal / Q000097:blood / Q000139:chemically induced; D008297:Male; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000097:blood / Q000188:drug therapy; D000069442:Natalizumab / Q000009:adverse effects*
chemical_list: D000914:Antibodies, Viral; D007155:Immunologic Factors; D000069442:Natalizumab
keywords: John Cunningham Virus (JCV); Multiple sclerosis; natalizumab; progressive multifocal leukoencephalopathy (PML)